Get the Daily Brief
Latest Biotech News
FDA Outlines Rare Disease Evidence Principles for Ultra-Rare Drug Approvals
The FDA announced the Rare Disease Evidence Principles (RDEP) program, a new review pathway designed to facilitate the development and approval of drugs targeting ultra-rare genetic diseases...
Novartis and Arrowhead Expand RNAi Collaboration with $2.2 Billion Deal
Novartis and Arrowhead Pharmaceuticals have entered a substantial global licensing and collaboration agreement for Arrowhead’s preclinical siRNA therapy ARO-SNCA, targeting synucleinopathies...
Innovative Protein Tool 'Crunch' Programmed for Targeted Cell Clearance
Researchers at Kyoto University’s Institute for Integrated Cell-Material Sciences developed 'Crunch,' a synthetic protein-based therapeutic designed to selectively induce phagocytosis of unwanted...
Biogenic Production of Biodegradable Plastic Alternative PDCA by Engineered E. coli
A study from Kobe University bioengineers announced the successful biosynthesis of pyridinedicarboxylic acid (PDCA), a biodegradable alternative to petroleum-based plastics such as polyethylene...
AI-Driven Machine Learning Enhances Cancer Diagnosis and Prognosis
In notable advances within oncology and computational biology, multiple teams have developed and applied machine learning tools to refine cancer diagnostics and prognostication. A Chinese research...
Leadership Turmoil at HHS and CDC Amid Vaccine Policy Disputes
The U.S. Department of Health and Human Services (HHS) and the Centers for Disease Control and Prevention (CDC) face significant internal turmoil under Secretary Robert F. Kennedy Jr.’s...
FDA Unveils Rare Disease Evidence Principles for Ultra-Rare Drug Approvals
The FDA announced a novel Rare Disease Evidence Principles (RDEP) pathway aimed at expediting the development and review of drugs targeting ultra-rare genetic conditions affecting fewer than 1,000...
Treeline Biosciences Emerges With $200M Extension and Clinical Pipeline Reveal
Treeline Biosciences, a clinical-stage oncology biotech, disclosed a $200 million extension to its Series A round, bringing total funding to $1.1 billion. Alongside the financing, the company...
Novartis and Arrowhead Form $200M Collaboration on RNAi Parkinson’s Therapy
Novartis committed $200 million upfront to Arrowhead Pharmaceuticals to license and co-develop ARO-SNCA, an RNA interference therapy targeting alpha-synuclein protein implicated in Parkinson’s...
Wave Life Sciences Reports Mixed Data on RNA Editing Therapy for Alpha-1 Antitrypsin Deficiency
Wave Life Sciences released additional data from a phase Ib/IIa trial of its RNA-editing oligonucleotide WVE-006 for alpha-1 antitrypsin deficiency. Despite demonstrating target engagement and...
Sanofi’s Amlitelimab Eczema Drug Meets Trial Endpoints but Disappoints Investors
Sanofi reported that its Phase 3 trial for amlitelimab, an anti-OX40L antibody for atopic dermatitis, successfully met primary and key secondary endpoints including skin clearance and disease...
FDA Delays Agios Pharmaceuticals’ Pyrukynd Decision Over Liver Safety Review
The FDA extended its decision deadline by three months for Agios Pharmaceuticals’ drug Pyrukynd, a treatment candidate for thalassemia, to allow for additional review of a liver safety mitigation...
Mercy BioAnalytics Raises $59 Million to Launch Early Cancer Detection Tests
Mercy BioAnalytics secured $59 million in Series B funding to commercialize its blood-based ovarian cancer screening test, targeting average-risk post-menopausal women and those with pelvic...
AC Immune Cuts Workforce, Prioritizes Parkinson’s and Neurodegenerative Programs
Swiss biotech AC Immune announced a 30% reduction in staff alongside a strategic pipeline downsizing, preserving cash runway extension of approximately six months. The company will deprioritize at...
BioMérieux Reports Modest 1% Revenue Growth Amid Product Mix Shifts
In Q2 2025, BioMérieux saw revenues rise 1% year-over-year to €945.9 million, driven by molecular biology clinical application gains offsetting weaknesses in immunoassays. Sales of molecular...
SeqOne Acquires Congenica, Enhances Clinical Interpretation for US Expansion
French genomics software firm SeqOne completed the acquisition of UK-based Congenica, gaining a CE-marked in vitro diagnostic clinical decision support platform and clinical interpretation...
Novartis Bets $200 Million on Arrowhead’s RNAi Therapy for Parkinson’s
Novartis has entered a global license and collaboration agreement with Arrowhead Pharmaceuticals, investing $200 million upfront to develop Arrowhead's preclinical siRNA therapy ARO-SNCA targeting...
Treeline Biosciences Unveils $1.1 Billion Pipeline with Three Cancer Drugs in Clinic
Treeline Biosciences emerged from stealth with a $200 million Series A extension, raising its total funding to over $1.1 billion. The Massachusetts-based biotech disclosed its lead cancer drug...
FDA Acceptance to Waive Clinical Efficacy Studies for Biosimilars
Professor Sarfaraz K. Niazi achieved a historic regulatory milestone with the FDA accepting the waiver of clinical efficacy studies (CESs) for monoclonal antibody biosimilars. This paradigm shift...
Ionis Pharmaceuticals Expands Lipid-Lowering Drug Use After Successful Trials
Ionis Pharmaceuticals reported positive Phase 3 results for Tryngolza in severe hypertriglyceridemia (sHTG), demonstrating significant reductions in triglyceride levels and pancreatitis prevention...